Stock fact sheet · data as of

InspireMD, Inc. (NSPR): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · Speculative / Distressed

Close0.4804
GLS fair value-no model value
Margin of safety-
Wheel Score32Weakout of 100
Health2/9Piotroski F-score
Moat2.7/10GLS 10-year score
Market cap$22M58k shares a day
Implied vol.332%near-the-money, 20-60 d
P/E-EPS -0.52
Dividend yieldnone
Beta0.83about the market
Next earnings10 Nov 2026in 25 days

Is NSPR undervalued?

At 0.4804 (close of 16 Oct 2026), NSPR has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -0.52 and it pays no dividend), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.

The nightly engine files NSPR under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for NSPR

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)1.02+112%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target3.50+629%Analysts' average 12-month price target. Not in the average

Quality and financial health

InspireMD, Inc. scores only 2 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 2.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC -83.4%, ROE -88.4%, ROA -70.3% - with debt at 0.06 times equity and negative free cash flow.

InspireMD, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from CGuard EPS 100% (quarter Q3 FY2023).

Institutional ownership scores 4/10, insider activity 9/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score2 / 9ROIC-83.4%
GLS Moat2.7 / 10ROE-88.4%
Debt / equity0.06ROA-70.3%
Free-cash-flow yield-190.1%Payout ratio0%
Institutions4 / 10Insiders · Congress9 · 5 / 10

Wheel Score 32: Weak

With a Wheel Score of 32 InspireMD, Inc. sits in the Weak band. The parts - Value 13/25, Health 4/20, Moat 4/15, Premium 5/20, Stability 6/20 - show where: Health (4/20) scores lowest.

Implied volatility is 332%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is thin - 461 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.

Volume runs at 58k shares a day on a market cap of $22M, with a beta of 0.83; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value13 / 250% margin of safety
Health4 / 20Piotroski 2/9
Moat4 / 15moat 2.7/10
Premium5 / 20implied volatility 332%
Stability6 / 2058k shares/day, $22M cap, beta 0.83

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 10 Nov 2026, 25 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to InspireMD, Inc. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
ARAY
Accuray Incorporated
0.1738--37Weak$21M
BDMD
Baird Medical Investment Holdings Limited
0.60002.56+77%39No options$19M
PMI
Picard Medical, Inc.
12.68--33No options$26M
GTHP
Guided Therapeutics, Inc.
0.1900--27No options$18M
PETV
PetVivo Holdings, Inc.
0.7400--30No options$28M
MODD
Modular Medical, Inc.
2.162.46+12%34No options$18M
NSYS
Nortech Systems Incorporated
10.3215.29+33%39No options$29M
HSCS
HeartSciences Inc.
3.18--21No options$15M
PAVM
PAVmed Inc.
2.29--24No options$15M
IRIX
IRIDEX Corporation
0.8244--33Weak$14M
QTI
QT Imaging Holdings, Inc.
2.50--32No options$37M
CVRX
CVRx, Inc.
1.39--36Weak$37M

⚖ Compare NSPR with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about NSPR

Is NSPR undervalued right now?

The GLS models could not value NSPR (the company lost money over the last twelve months, EPS -0.52 and it pays no dividend), so there is no fair value or margin of safety to compare the price of 0.4804 against.

What is the Wheel Score of NSPR and what does it mean?

NSPR scores 32 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for NSPR?

None of the nine GLS models produced a positive value for NSPR (the company lost money over the last twelve months, EPS -0.52 and it pays no dividend), so there is no GLS fair value tonight.

When does InspireMD, Inc. report earnings next?

The next earnings report is due on 10 Nov 2026, 25 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does NSPR have listed options, and how liquid are they?

Yes. The nightly snapshot found 30 listed contracts with 461 open interest across all expiries and implied volatility of 332% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.